Summarized by Masters of Longevity from Longevity Technology.
NeuroXT’s AI medical imaging tool takes center stage in an article about its regulatory milestone and plans for clinical adoption and commercialization.
Key Takeaways
- NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer’s Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- NeuroXT Inc announced that NEXT-Cue, its AI-based Software as a Medical Device supporting prognostic assessment in patients with mild cognitive impairment, has received 510(k) clearance from the U.S.
- The company claims it will advance U.S.
